- Home
- EGHT vs INBX Comparison
EGHT vs INBX Comparison
Compare EGHT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGHT
- INBX
- Stock Information
- Founded
- EGHT 1987
- INBX 2010
- Country
- EGHT United States
- INBX United States
- Employees
- EGHT N/A
- INBX N/A
- Industry
- EGHT EDP Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- EGHT Technology
- INBX Health Care
- Exchange
- EGHT Nasdaq
- INBX Nasdaq
- Market Cap
- EGHT 250.2M
- INBX 237.5M
- IPO Year
- EGHT 1997
- INBX 2020
- Fundamental
- Price
- EGHT $1.85
- INBX $16.10
- Analyst Decision
- EGHT Buy
- INBX Hold
- Analyst Count
- EGHT 6
- INBX 1
- Target Price
- EGHT $2.83
- INBX N/A
- AVG Volume (30 Days)
- EGHT 876.5K
- INBX 112.3K
- Earning Date
- EGHT 10-30-2024
- INBX 08-13-2024
- Dividend Yield
- EGHT N/A
- INBX N/A
- EPS Growth
- EGHT N/A
- INBX N/A
- EPS
- EGHT N/A
- INBX 118.83
- Revenue
- EGHT $723,565,000.00
- INBX $1,687,000.00
- Revenue This Year
- EGHT $0.85
- INBX N/A
- Revenue Next Year
- EGHT $2.15
- INBX N/A
- P/E Ratio
- EGHT N/A
- INBX $0.13
- Revenue Growth
- EGHT N/A
- INBX 24.26
- 52 Week Low
- EGHT $1.51
- INBX $10.80
- 52 Week High
- EGHT $3.92
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- EGHT 42.97
- INBX 55.90
- Support Level
- EGHT $1.89
- INBX $14.67
- Resistance Level
- EGHT $2.20
- INBX $16.35
- Average True Range (ATR)
- EGHT 0.10
- INBX 0.65
- MACD
- EGHT -0.00
- INBX -0.09
- Stochastic Oscillator
- EGHT 1.35
- INBX 45.59
About EGHT 8x8 Inc
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.